CN116669737A - 毒蕈碱型乙酰胆碱受体m4的拮抗剂 - Google Patents

毒蕈碱型乙酰胆碱受体m4的拮抗剂 Download PDF

Info

Publication number
CN116669737A
CN116669737A CN202180087480.8A CN202180087480A CN116669737A CN 116669737 A CN116669737 A CN 116669737A CN 202180087480 A CN202180087480 A CN 202180087480A CN 116669737 A CN116669737 A CN 116669737A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
alkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180087480.8A
Other languages
English (en)
Chinese (zh)
Inventor
A·M·本德尔
M·斯波克
M·A·科尔克马兹-瓦伊塞斯
C·A·马林凯
P·J·康恩
C·W·林斯利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Priority claimed from PCT/US2021/064776 external-priority patent/WO2022140499A1/en
Publication of CN116669737A publication Critical patent/CN116669737A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202180087480.8A 2020-12-22 2021-12-22 毒蕈碱型乙酰胆碱受体m4的拮抗剂 Pending CN116669737A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US63/129,196 2020-12-22
US63/170,899 2021-04-05
US63/208,877 2021-06-09
US202163284750P 2021-12-01 2021-12-01
US63/284,750 2021-12-01
PCT/US2021/064776 WO2022140499A1 (en) 2020-12-22 2021-12-22 Antagonists of the muscarinic acetylcholine receptor m4

Publications (1)

Publication Number Publication Date
CN116669737A true CN116669737A (zh) 2023-08-29

Family

ID=84943708

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180087480.8A Pending CN116669737A (zh) 2020-12-22 2021-12-22 毒蕈碱型乙酰胆碱受体m4的拮抗剂
CN202280088712.6A Pending CN118541365A (zh) 2021-12-01 2022-12-01 毒蕈碱型乙酰胆碱受体m4的拮抗剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202280088712.6A Pending CN118541365A (zh) 2021-12-01 2022-12-01 毒蕈碱型乙酰胆碱受体m4的拮抗剂

Country Status (10)

Country Link
US (1) US20250145595A1 (cg-RX-API-DMAC10.html)
EP (1) EP4441046A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024543973A (cg-RX-API-DMAC10.html)
KR (1) KR20240112343A (cg-RX-API-DMAC10.html)
CN (2) CN116669737A (cg-RX-API-DMAC10.html)
AU (1) AU2022400780A1 (cg-RX-API-DMAC10.html)
CA (1) CA3241298A1 (cg-RX-API-DMAC10.html)
IL (1) IL313219A (cg-RX-API-DMAC10.html)
MX (1) MX2024006718A (cg-RX-API-DMAC10.html)
WO (1) WO2023102100A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3651762B1 (en) 2017-07-12 2024-07-03 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
JP7270989B2 (ja) 2017-10-20 2023-05-11 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
US12319701B2 (en) 2019-10-04 2025-06-03 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
JP2024500880A (ja) * 2020-12-22 2024-01-10 ヴァンダービルト ユニヴァーシティ ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
WO2022261427A1 (en) 2021-06-11 2022-12-15 Vanderbilt University (4-(6-((2-octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-lambda6- sulfanone derivatives and similar compounds as muscarinic acetylcholine receptor m4 antagonists for the treatment of neurodegenerative disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109310668A (zh) * 2016-06-22 2019-02-05 范德比尔特大学 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
WO2019032654A1 (en) * 2017-08-08 2019-02-14 Vanderbilt University ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4
CN111491920A (zh) * 2017-10-20 2020-08-04 范德比尔特大学 毒蕈碱性乙酰胆碱受体m4的拮抗剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021119254A1 (en) * 2019-12-10 2021-06-17 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
US20230183219A1 (en) * 2020-04-24 2023-06-15 Vanderbilt University Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4
CA3180717A1 (en) * 2020-04-24 2021-10-28 Vanderbilt University Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109310668A (zh) * 2016-06-22 2019-02-05 范德比尔特大学 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
WO2019032654A1 (en) * 2017-08-08 2019-02-14 Vanderbilt University ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4
CN111491920A (zh) * 2017-10-20 2020-08-04 范德比尔特大学 毒蕈碱性乙酰胆碱受体m4的拮抗剂

Also Published As

Publication number Publication date
KR20240112343A (ko) 2024-07-18
AU2022400780A1 (en) 2024-06-20
CA3241298A1 (en) 2023-06-08
US20250145595A1 (en) 2025-05-08
CN118541365A (zh) 2024-08-23
WO2023102100A1 (en) 2023-06-08
JP2024543973A (ja) 2024-11-26
MX2024006718A (es) 2024-08-09
EP4441046A1 (en) 2024-10-09
IL313219A (en) 2024-07-01

Similar Documents

Publication Publication Date Title
CN118063442A (zh) 毒蕈碱性乙酰胆碱受体m4的拮抗剂
CN118541365A (zh) 毒蕈碱型乙酰胆碱受体m4的拮抗剂
EP4267569B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
JP2023522959A (ja) ムスカリンアセチルコリン受容体ｍ４のアンタゴニストとしての縮合置換ヒドロピロール
AU2021261002A1 (en) Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4
US20230150986A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
WO2022212819A1 (en) Indazole derivatives as antagonists of the muscarinic acetylcholine receptor m4
AU2021381350A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
AU2020358000A1 (en) Antagonists of the muscarinic acetylcholine receptor M4
WO2022261427A1 (en) (4-(6-((2-octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-lambda6- sulfanone derivatives and similar compounds as muscarinic acetylcholine receptor m4 antagonists for the treatment of neurodegenerative disorders
WO2022036177A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
WO2024036183A1 (en) Antagonists of 5-hydroxytryptamine receptor subtype 2b
HK40115503A (en) Antagonists of the muscarinic acetylcholine receptor m4
HK40097532A (en) Antagonists of the muscarinic acetylcholine receptor m4
HK40121280A (en) Antagonists of the muscarinic acetylcholine receptor m4
WO2024158745A1 (en) Inhibitors of lrrk2

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40097532

Country of ref document: HK